Display options
Share it on

Mol Ther Methods Clin Dev. 2020 Jul 09;18:595-606. doi: 10.1016/j.omtm.2020.07.008. eCollection 2020 Sep 11.

Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design.

Molecular therapy. Methods & clinical development

Saba Ghassemi, Francisco J Martinez-Becerra, Alyssa M Master, Sarah A Richman, David Heo, John Leferovich, Yitao Tu, Juan Carlos García-Cañaveras, Asma Ayari, Yinan Lu, Ai Wang, Joshua D Rabinowitz, Michael C Milone, Carl H June, Roddy S O'Connor

Affiliations

  1. Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  2. Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.
  3. Nucleus Biologics, LLC, San Diego, CA, USA.
  4. Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  5. Department of Biological Physics, University of Pennsylvania, Philadelphia, PA, USA.
  6. Department of Chemistry, Princeton University, Princeton, NJ, USA.
  7. Lewis-Singer Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.

PMID: 32775494 PMCID: PMC7397397 DOI: 10.1016/j.omtm.2020.07.008

Abstract

Effective chimeric antigen receptor (CAR)-T cell therapy is dependent on optimal cell culture methods conducive to the activation and expansion of T cells

© 2020 The Author(s).

References

  1. Cancer Immunol Res. 2018 Sep;6(9):1100-1109 - PubMed
  2. Med Sci Sports Exerc. 2019 Oct;51(10):2098-2108 - PubMed
  3. N Engl J Med. 2014 Oct 16;371(16):1507-17 - PubMed
  4. Sci Transl Med. 2015 Feb 18;7(275):275ra22 - PubMed
  5. Exp Physiol. 2018 Jun;103(6):783-789 - PubMed
  6. Cancer Immunol Immunother. 2018 Jan;67(1):25-38 - PubMed
  7. Nature. 2017 Mar 2;543(7643):113-117 - PubMed
  8. Immunity. 2016 Feb 16;44(2):380-90 - PubMed
  9. PLoS One. 2009 Oct 07;4(10):e7325 - PubMed
  10. Sci Rep. 2018 Feb 15;8(1):3101 - PubMed
  11. Cancer Immunol Res. 2018 Jan;6(1):36-46 - PubMed
  12. Physiol Rev. 2013 Oct;93(4):1803-45 - PubMed
  13. Tissue Eng Part A. 2015 Nov;21(21-22):2714-22 - PubMed
  14. Acta Physiol (Oxf). 2019 Mar;225(3):e13207 - PubMed
  15. Immunol Cell Biol. 2011 Jan;89(1):111-21 - PubMed
  16. J Immunol Res. 2019 Sep 4;2019:3616120 - PubMed
  17. Cell. 2016 Oct 20;167(3):829-842.e13 - PubMed
  18. Sci Rep. 2018 Apr 19;8(1):6289 - PubMed
  19. Nat Rev Immunol. 2019 May;19(5):324-335 - PubMed
  20. Cell. 2017 Apr 06;169(2):258-272.e17 - PubMed
  21. J Immunol. 2012 Aug 1;189(3):1330-9 - PubMed
  22. Neuron. 2006 Jul 20;51(2):187-99 - PubMed
  23. Science. 2018 Mar 23;359(6382):1361-1365 - PubMed
  24. Cytotherapy. 2019 Sep;21(9):911-924 - PubMed
  25. J Neurosci. 2001 May 15;21(10):3483-91 - PubMed
  26. Nat Med. 2018 May;24(5):563-571 - PubMed
  27. Methods. 2018 Jan 15;133:54-64 - PubMed
  28. J Tissue Eng Regen Med. 2018 Feb;12(2):557-564 - PubMed
  29. Nat Rev Mol Cell Biol. 2009 Aug;10(8):513-25 - PubMed
  30. J Clin Invest. 2013 Oct;123(10):4479-88 - PubMed
  31. Mech Ageing Dev. 2000 Dec 20;121(1-3):203-15 - PubMed

Publication Types